Publisher's Synopsis
Since 1978, when Sandimmun was first used in humans, great experience has been gathered in clinical transplantation by the treatment of about half a million patients. The experience with Sandimmun in nephrotic syndrome is put into perspective and compared with alternatives such as corticosteroids and cytotoxic agents. Sandimmun may be regarded as a leap forward in the treatment of that population of patients that do not satisfactorily respond to steroids. The possibility of drastically reducing the use of corticosteroids, particularly in children, is perhaps the most attractive feature of Sandimmun. This book gives the results ofa worldwide clinical programme. It includes authors' personal experience as well as an analysis of all data made available. A careful assessment of reported side effects is also given.
